BARBARA ANN KARMANOS CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1995-01-01

Employees: 5K

Market Cap: -

Website: http://www.karmanos.org

Clinical Trials

Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer

Phase 2

Not yet recruiting

Conditions: Metastatic Pancreatic Adenocarcinoma

Interventions: Drug: Nab paclitaxel
Drug: Gemcitabine
Device: TheraBionic P1

First Posted Date: 2024-08-28

Last Posted Date: 2024-08-28

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 30

Registration Number: NCT06576115

Locations: 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Iberdomide
Drug: Daratumumab/rHuPH20 Co-formulation

First Posted Date: 2023-10-30

Last Posted Date: 2024-05-16

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 60

Registration Number: NCT06107738

Locations: 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

Dietary Reporting In The Amyloidoses

Not Applicable

Recruiting

Conditions: Amyloidosis

Interventions: Other: Tracking Dietary/Supplement Intake on MyFitnessPal smartphone application (app)

First Posted Date: 2023-02-21

Last Posted Date: 2023-05-08

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 40

Registration Number: NCT05738005

Locations: 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

F-Tryptophan PET/CT in Human Cancers

Phase 1

Recruiting

Conditions: Metastatic Brain Tumor
Intracranial Glioma
Neuroendocrine Tumors
Rectal Cancer
Breast Cancer

Interventions: Drug: 1-(2-[18F]FLUOROETHYL)-L-Tryptophan

First Posted Date: 2022-09-27

Last Posted Date: 2024-02-23

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 24

Registration Number: NCT05556473

Locations: 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant

Phase 2

Withdrawn

Conditions: Relapsed Diffuse Large B-cell Lymphoma

Interventions: Drug: loncastuximab tesirine

First Posted Date: 2022-02-03

Last Posted Date: 2023-11-01

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT05222438

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia
Multiple Myeloma
AL Amyloidosis

Interventions: Drug: A single "booster" dose of the Moderna mRNA COVID-19 vaccine

First Posted Date: 2021-08-31

Last Posted Date: 2023-12-20

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 119

Registration Number: NCT05028374

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Ask Questions (ASQ):Implementation of a Communication Intervention

Not Applicable

Completed

Conditions: Stage II Colorectal Cancer
Stage III Colorectal Cancer
Stage II Lung Cancer
Stage III Lung Cancer
Stage III Ovarian Cancer
Stage III Bladder Cancer
Stage IV Breast Cancer
Stage IV Lung Cancer
Stage II Prostate Cancer
Stage III Prostate Cancer

Interventions: Behavioral: Behavioral Intervention

First Posted Date: 2021-08-27

Last Posted Date: 2023-08-16

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 81

Registration Number: NCT05025748

Locations: 🇺🇸
Karmanos Cancer Institute at McLaren Clarkston, Clarkston, Michigan, United States
🇺🇸
Karmanos Cancer Institute at McLaren Bay Region, Bay City, Michigan, United States
🇺🇸
Karmanos Cancer Institute at McLaren Flint, Flint, Michigan, United States

and more 5 locations

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

Phase 2

Recruiting

Conditions: Diffuse Large B-Cell Lymphoma
High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements
High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements
Double Expressor Lymphoma
High-grade B-cell Lymphoma

Interventions: Drug: Prednisone
Drug: Prednisolone
Drug: Methylprednisolone
Biological: Rituximab
Drug: Polatuzumab Vedotin
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride

First Posted Date: 2020-07-21

Last Posted Date: 2024-03-20

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 49

Registration Number: NCT04479267

Locations: 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma

Phase 1

Active, not recruiting

Conditions: Glioblastoma
Gliosarcoma

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Radiation: Intensity-Modulated Radiation Therapy (IMRT)
Drug: Temozolomide
Drug: Chloroquine
Procedure: Tumor Treating Fields Therapy (TTF)

First Posted Date: 2020-05-21

Last Posted Date: 2024-03-26

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 2

Registration Number: NCT04397679

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer

Not Applicable

Completed

Conditions: Chronic Lymphocytic Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Plasma Cell Myeloma

Interventions: Behavioral: The DISCO App
Behavioral: Usual Care

First Posted Date: 2020-02-24

Last Posted Date: 2023-05-03

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 25

Registration Number: NCT04282343

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy